Cell Receptor has identified a group of fairly well tolerated substances with a remarkable ability to prevent growing benign and malignant cells from absorbing growth factors. The goal is to discover a part of a transport mechanism that has not been considered therapeutically so far.

The project was born in the cell culture laboratory and is now in the translational phase, with the aim of clinical application.

We are convinced that the new therapy has the potential to inhibit the seeding of metastases of malignant tumours. We also expect that it will enable the containment of pathological immune reactions of autoimmune diseases, as autoimmunity is associated with the proliferation of cells in the immune system. We estimate the annual serviceable obtainable global demand (SOM) to be more than CHF 8.5 billion.

The project has now reached a stage where proof of concept is to be provided by means of a clinical trial. The Type IIa study is intended to address the prevention of metastases and will be conducted by a renowned oncology organization. The study will be relatively inexpensive due to very special organisational and legal circumstances. Cell Receptor will finance the study and is currently seeking venture capital for this purpose and welcomes suitable scientific and financial partnerships.

Are you interested in our project? Then we kindly ask you to contact us.